文献速递泌尿男性生殖肿瘤

高危肾细胞癌患者辅助舒尼替尼治疗:S-TRAC试验中的安全性、治疗管理和患者报告结局

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.
PubMed 文献 · Ann Oncol · 2018-01-01

S-TRAC试验中,高危肾细胞癌术后患者随机接受舒尼替尼(50 mg/日)或安慰剂,舒尼替尼组无病生存期显著优于安慰剂(HR 0.76;95%CI 0.59-0.98;双侧P=0.03)。舒尼替尼组不良事件可预测、可管理且可逆,患者报告总体健康状况评分显著低于安慰剂但无临床意义,腹泻和食欲减退有临床意义的加重。

要点

  • 舒尼替尼组关键不良事件的中位发生时间约1个月,中位缓解时间约3.5周。
  • 导致永久停药的不良事件中40.6%为1/2级,87.2%在末次治疗后28天内缓解或正在缓解。
  • 舒尼替尼组总体健康状况评分显著低于安慰剂但无临床意义,腹泻和食欲减退有临床意义加重。

核心结论

  • S-TRAC试验中,舒尼替尼组不良事件可预测、可管理,通过剂量中断、剂量减量和/或标准支持治疗可逆。
  • 舒尼替尼组患者报告症状增加和健康相关生活质量降低,但除食欲减退和腹泻外一般无临床意义,属舒尼替尼已知效应的预期表现。

研究设计与样本

  • S-TRAC试验为随机对照试验,患者按UCLA整合分期系统和ECOG体能状态评分分层,按1:1随机接受舒尼替尼(50 mg/日)或安慰剂。
  • 通过单次剂量减至37.5 mg、剂量延迟和剂量中断管理不良事件。
  • 采用EORTC QLQ-C30评估健康相关生活质量及舒尼替尼相关关键症状。

主要发现

  • 舒尼替尼组和安慰剂组平均治疗持续时间分别为9.5个月(标准差4.4)和10.3个月(标准差3.7)。
  • 舒尼替尼组关键不良事件中位发生时间约在治疗开始后1个月,中位缓解时间约3.5周。
  • 导致永久停药的不良事件中40.6%为1/2级,87.2%在末次治疗后28天内缓解或正在缓解。
  • 舒尼替尼组EORTC QLQ-C30总体健康状况评分显著低于安慰剂组,但降低无临床意义。
  • 患者报告腹泻和食欲减退有临床意义的加重。

关键数值与推荐

  • 舒尼替尼组无病生存期显著优于安慰剂(HR 0.76;95%CI 0.59-0.98;双侧P=0.03)。
  • 舒尼替尼剂量为50 mg/日,单次剂量减至37.5 mg用于管理不良事件。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant sunitinib has significantly improved disease-free survival versus placebo in patients with renal cell carcinoma at high risk of recurrence post-nephrectomy (hazard ratio 0.76; 95% confidence interval, 0.59-0.98; two-sided P = 0.03). We report safety, therapy management, and patient-reported outcomes for patients receiving sunitinib and placebo in the S-TRAC trial. PATIENTS AND METHODS: Patients were stratified by the University of California, Los Angeles Integrated Staging System and Eastern Cooperative Oncology Group performance status score, and randomized (1 : 1) to receive sunitinib (50 mg/day) or placebo. Single dose reductions to 37.5 mg, dose delays, and dose interruptions were used to manage adverse events (AEs). Patients' health-related quality of life, including key symptoms typically associated with sunitinib, were evaluated with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). RESULTS: Patients maintained treatment for 9.5 (mean, SD 4.4) and 10.3 (mean, SD 3.7) months in the sunitinib and placebo arms, respectively. In the sunitinib arm, key AEs occurred ∼1 month (median) after start of treatment and resolved within ∼3.5 weeks (median). Many (40.6%) AEs leading to permanent discontinuation were grade 1/2, and most (87.2%) resolved or were resolving by 28 days after last treatment. Patients taking sunitinib showed a significantly lower EORTC QLQ-C30 overall health status score versus placebo, although this reduction was not clinically meaningful. Patients reported symptoms typically related to sunitinib treatment with diarrhea and loss of appetite showing clinically meaningful increases. CONCLUSIONS: In S-TRAC, AEs were predictable, manageable, and reversible via dose interruptions, dose reductions, and/or standard supportive medical therapy. Patients on sunitinib did report increased symptoms and reduced HRQoL, but these changes were generally not clinically meaningful, apart from appetite loss and diarrhea, and were expected in the context of known sunitinib effects. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT00375674.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Staehler M, Motzer RJ, George DJ, et al. Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. Ann Oncol. 2018. PMID: 30412222. doi:10.1093/annonc/mdy329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。